Pro Pharmaceutical: Fluorometholone raw material approved, specifications 20kg/barrel and 40kg/barrel.

Prolo Pharmaceutical announced that its wholly-owned subsidiary, Zhejiang Prolo Jiayuan Pharmaceutical Co., Ltd., has recently received the approval notice for the chemical raw material drug application for Fluorouracil () issued by the National Medical Products Administration. The specifications are 20kg/barrel and 40kg/barrel. Fluorouracil tablets are KRAS G12C inhibitors used for the treatment of adult patients with advanced non-small cell lung cancer with KRAS G12C mutations who have received at least one systemic therapy. This tablet was approved for marketing in mainland China in August 2024 and is expected to be included in the national medical insurance drug list by the end of 2025. The company stated that this approval will have a positive impact on its future operations.